63057-72-7

Usage

Uses

Used in Organic Synthesis:
1-(BENZYLOXY)-4-BROMO-2-METHOXYBENZENE is used as a key intermediate in the synthesis of various organic compounds. Its reactivity towards nucleophilic substitution reactions allows for the formation of a wide range of derivatives, making it a versatile building block in the development of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1-(BENZYLOXY)-4-BROMO-2-METHOXYBENZENE is used as a starting material for the synthesis of drug candidates. Its unique structural features, including the benzyloxy and methoxy groups, can be exploited to design molecules with specific biological activities, such as antimicrobial, anti-inflammatory, or analgesic properties.
Used in Agrochemical Industry:
1-(BENZYLOXY)-4-BROMO-2-METHOXYBENZENE is also utilized in the agrochemical industry as a precursor for the development of new pesticides and herbicides. Its reactivity and structural diversity enable the creation of compounds with improved efficacy and selectivity, contributing to more sustainable agricultural practices.
Used in Specialty Chemicals:
In the specialty chemicals sector, 1-(BENZYLOXY)-4-BROMO-2-METHOXYBENZENE is employed as a raw material for the production of various high-value compounds, such as fragrances, dyes, and polymer additives. Its unique chemical properties allow for the creation of novel products with enhanced performance characteristics, meeting the demands of diverse applications.

Upstream product

• 100-39-0 benzyl bromide 
• 2316-64-5 5-bromo-2-hydroxybenzyl alcohol 
• 7368-78-7 4-bromoguaiacol 
• 1486-52-8 3-methoxy-4-benzyloxybenzoyl chloride 
• 100-44-7 benzyl chloride 

Downstream Products

• 935431-23-5 (2R,3R,4R)-4-(4-allyloxy-3-methoxyphenyl)-1-(4-benzyloxy-3-methoxyphenyl)-4-(tert-butyldimethylsilanyloxy)-2,3-dimethylbutan-1-ol 
• 845655-19-8 1-(4-Benzyloxy-3-methoxy-phenyl)-1H-pyrazole 
• 923287-84-7 (4-benzyloxy-3-methoxy-phenyl)-(2-trifluoromethyl-pyridin-3-yl)-methanone 
• 134987-32-9 2-(4-benzyloxy-3-methoxyphenylthio)benzoic acid 
• 125629-32-5 (3-methoxy-4-benzyloxyphenyl)(4-pyridyl)methanol 
• 64881-05-6 1-<4-(benzyloxy)-3-methoxyphenyl>ethan-2-ol 
• 36798-09-1 1-(benzyloxy)-4-bromo-2-methoxy-5-nitrobenzene 
• 2380-78-1 homovanillyl alcohol 
• 243990-53-6 (4-(benzyloxy)-3-methoxyphenyl)boronic acid 
• 97746-19-5 4'-benzyloxy-3',5,7-trimethoxy-4-phenyl-2H-1-benzopyran-2-one 
• 125629-00-7 3,4-dihydroxy-5-nitrophenyl 4-pyridyl ketone 
• 125629-33-6 4-benzyloxy-3-methoxyphenyl 4-pyridyl ketone 
• 125629-35-8 4-hydroxy-3-methoxy-5-nitrophenyl 4-pyridyl ketone 
• 125629-34-7 4-hydroxy-3-methoxyphenyl 4-pyridyl ketone 

Relevant academic research and scientific papers

Structure-based design, docking and binding free energy calculations of a366 derivatives as spindlin1 inhibitors

The chromatin reader protein Spindlin1 plays an important role in epigenetic regulation, through which it has been linked to several types of malignant tumors. In the current work, we report on the development of novel analogs of the previously published lead inhibitor A366. In an effort to improve the activity and explore the structure–activity relationship (SAR), a series of 21 derivatives was synthesized, tested in vitro, and investigated by means of molecular modeling tools. Docking studies and molecular dynamics (MD) simulations were performed to analyze and rationalize the structural differences responsible for the Spindlin1 activity. The analysis of MD simulations shed light on the important interactions. Our study highlighted the main structural features that are required for Spindlin1 inhibitory activity, which include a positively charged pyrrolidine moiety embedded into the aromatic cage connected via a propyloxy linker to the 2-aminoindole core. Of the latter, the amidine group anchor the compounds into the pocket through salt bridge interactions with Asp184. Different protocols were tested to identify a fast in silico method that could help to discriminate between active and inactive compounds within the A366 series. Rescoring the docking poses with MM-GBSA calculations was successful in this regard. Because A366 is known to be a G9a inhibitor, the most active developed Spindlin1 inhibitors were also tested over G9a and GLP to verify the selectivity profile of the A366 analogs. This resulted in the discovery of diverse selective compounds, among which 1s and 1t showed Spindlin1 activity in the nanomolar range and selectivity over G9a and GLP. Finally, future design hypotheses were suggested based on our findings.

Rapid Bis-Coupling Reactivity with Triarylbismuth Reagents: Synthesis of Structurally Diverse Scaffolds and Step-economic Convergent Synthesis of Quebecol

The cross-coupling study of gem-dibromoesters with triarylbismuths as threefold arylating reagents was investigated under palladium-catalyzed conditions. This study using triarylbismuth reagents explored the cross-coupling reactivity with various functionalized gem-dibromoesters. It furnished a variety of multi-functional trisubstituted acrylates embedded with aryl, alkene and alkyne scaffolds in high yields. The present study in turn, provided easy access to various triarylated acrylates and functionalized 1,3-dienyl and 1,3-enyne esters. Further, the established method applied in the step-economic and convergent synthesis of quebecol natural product in good yield.

SUBSTITUTED FUSED BI- OR TRI- HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS

The present disclosure relates to substituted fused bi- or tri- heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., sickle cell anemia) via inhibit

AZAINDOLE COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS

The present disclosure provides certain angular tricyclic compounds that are histone methyltransferases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as cancers and hemoglobinopathies (e.g., beta-thalassemia and sickle cell disease). Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Anti-inflammatory properties of quebecol and its derivatives

Herein we report our results on the anti-inflammatory activity of quebecol, a polyphenolic compound discovered in maple syrup. Bioassays demonstrated that quebecol has an anti-inflammatory effect on LPS-induced NF-κB activation and inhibits the secretion of two pro-inflammatory cytokines, IL-6 and TNF-α. We also prepared and tested precursors of quebecol and its derivatives corresponding to its substructures of interest, with the aim to study the structure-activity relationships. Comparing the results obtained for all tested compounds allowed the identification of the main moiety responsible for the anti-inflammatory activity of quebecol.

Rapid Access to Benzofuran-Based Natural Products through a Concise Synthetic Strategy

A concise strategy is described for the synthesis of ailanthoidol (1), egonol (2), homoegonol (3), demethoxyegonol (4), demethoxyhomoegonol (5), and stemofuran A (6). This approach involves a Pd-catalysed domino cyclization/coupling process using triarylbismuth reagents for the generation of the benzofuran core. Subsequent structural modifications then give the final targets. The high yielding synthesis of the recently isolated natural products egonol-9(Z)-12(Z)-linoleate (2a), 7-demethoxyegonol-9(Z)-12(Z)-linoleate (4a), and 7-demethoxy-egonol-9(Z)-oleate (4b) are also reported.

Dihydropyrrolopyrazol-6-one MCHR1 antagonists for the treatment of obesity: Insights on in vivo efficacy from a novel FLIPR assay setup

Our investigation of the structure-activity and structure-liability relationships for dihydropyrrolopyrazol-6-one MCHR1 antagonists revealed that off-rate characteristics, inferred from potencies in a FLIPR assay following a 2 h incubation, can impact in

NOVEL COMPOUND FOR IMAGING TAU PROTEIN ACCUMULATED IN THE BRAIN

The present invention provides a compound represented by the following formula (I), a pharmaceutically acceptable salt thereof, or a solvate thereof. wherein: R1 and R2 are each separately selected from the group consisting of hydrog

Total synthesis of quebecol

We report here the total synthesis of quebecol, a new polyphenolic compound with potential applications recently isolated from maple syrup and produced during the condensation of the tree acer saccharum's sap. The synthetic approach we developed involves, as key steps, the formation of a dibromoalkene from an α-ketoester precursor followed by a double Suzuki-Miyaura reaction to unite the three aromatic rings of the target compound on a tetrasubstituted olefin precursor. Our methodology is an efficient pathway to the target compound and leads the way for future analogs.

PHENOLIC COMPOUNDS WITH ANTIOXIDANT AND ANTI-CANCER PROPERTIES, ANALOGS AND SYNTHESIS THEREOF

The present document describes a phytochemical isolated from maple syrup and composition comprising the same. More specifically, the document describes an antioxidant phytochemical compound, derivates thereof, and composition comprising the same. The document also describes a process of synthesizing the antioxidant phytochemical compound.